SUPRIYA LIFESCIENCE share price has zoomed 6% and is presently trading at Rs 744.0.
Meanwhile, the BSE HEALTHCARE index is at 42,675.4 (up 0.5%).
Among the top gainers in the BSE HEALTHCARE index today are APOLLO HOSPITALS (up 2.0%) and SUN PHARMA ADV. RES. (up 1.7%).
GSK Pharma (down 0.8%) and Natco Pharma (down 0.6%) are among the top losers today.
Over the last one year, SUPRIYA LIFESCIENCE has moved up from Rs 244.0 to Rs 744.0, registering a gain of Rs 500.0 (up 204.9%).
On the other hand, the BSE HEALTHCARE index has moved up from 29,583.1 to 42,675.4, registering a gain of 44.3% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 159.1%), SUVEN PHARMACEUTICALS (up 115.8%) and FORTIS HEALTHCARE (up 89.7%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 77,501.4 (up 0.4%).
The top gainers among the BSE Sensex today are ICICI Bank (up 1.7%) and SBI (up 1.6%). The most traded stocks in the BSE Sensex are MUNDRA PORT & SEZ and Tata Steel.
In the meantime, NSE Nifty is at 23,439.1 (up 0.4%). APOLLO HOSPITALS and ICICI Bank are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,655.2 to 77,501.4, registering a gain of 11,846.3 points (up 18.0%).
SUPRIYA LIFESCIENCE net profit grew 93.2% YoY to Rs 461 million for the quarter ended September 2024, compared to a profit of Rs 239 million a year ago. Net sales rose 18.6% to Rs 1,661 million during the period as against Rs 1,401 million in July-September 2023.
For the year ended March 2024, SUPRIYA LIFESCIENCE reported 32.6% increase in net profit to Rs 1,191 million compared to net profit of Rs 899 million during FY23. Revenue of the company grew 21.8% to Rs 4,938 million during FY24.
The current Price to earnings ratio of SUPRIYA LIFESCIENCE , based on rolling 12 month earnings, stands at 38.0.
Equitymaster requests your view! Post a comment on "SUPRIYA LIFESCIENCE Gains 6%; BSE HEALTHCARE Index Up 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!